Name	Eytan M. Stein
Current Position & Affiliation	Chief, Leukemia Service, Memorial Sloan Kettering Cancer Center
Country	United States
Major Field	Acute Myeloid Leukemia

Educational Background

College: University of Pennsylvania, Philadelphia, PA, USA
Medical School: Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Residency: Internal Medicine, Northwestern Memorial Hospital, Chicago, IL, USA
Fellowship: Hematology and Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY USA

Professional Experience

Assistant Member (Level 1)	Memorial Sloan Kettering Cancer Center, New York, NY
Instructor in Medicine	Weill Cornell Medical College, New York, NY
Assistant Member	Memorial Sloan-Kettering Cancer Center, New York, NY
Assistant Professor of Medicine	Weill Cornell Medical College, New York, NY
Associate Member	Memorial Sloan-Kettering Cancer Center, New York, NY
Chief, Leukemia Service, Associate Member	Memorial Sloan-Kettering Cancer Center, New York, NY

Other Experience and Professional Memberships

American Society of Hematology
American Society of Clinical Oncology
European Hematology Association
European Leukemia Network

Main Scientific Publications

1. **DiNardo CD*, Stein EM* (co-first authors),** de Botton S, Roboz GJ, Altman JK, Mims AS, Swords RT, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM. Ivosidenib induces durable remissions in IDH1-mutant relapsed/refractory AML *New England Journal of Medicine*,. 2018 Jun 21;378(25):2386-2398. DOI: 10.1056/NEJMoa1716984

2. Intlekofer AM*, Shih AH*, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud NR, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB†, Levine RL†, **Stein EM†.** Acquired clinical resistance to IDH inhibition through trans or cis dimer-interface mutations. *Nature*, 2018 Jul;559(7712):125-129. PMCID: PMC6121718

3. Issa GC, Aldoss I, DiPersio, J, Cuglievan B, Stone R, Arellano M, Thirman M, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, and **Stein EM**. The menin inhibitor Revumenib for KMT2A-rearranged or NPM1-mutant leukemia. *Nature. 2023 Mar;615(7954):920-924*

4. **Perner F, Stein EM** (co-first authors), Wenge DV, Singh S, Kim J, Apazidis A, Rahnamoun H, Anand D, Marinaccio C, Hatton C, Wen Y, Stone RM, Schaller D, Mowla S, Xiao W, Gamlen HA, Stonestrom AJ, Persaud S, Ener E, Cutler JA, Doench JG, McGeehan GM, Volkamer A, Chodera JD, Nowak RP, Fischer ES, Levine RL, Armstrong SA, Cai SF. MEN1 mutations mediate clinical resistance to menin inhibition. *Nature* 2023 Mar;615(7954):913-919.